MedTrace Logo

Hydroxychloroquine in Mild Graves' Orbitopathy

NCT05126147 · Status: RECRUITING · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 108

Last updated 2025-02-25

No results posted yet for this study

Summary

This study is aimed to investigate the effect of hydroxychloroquine in patients with mild Graves' orbitopathy (GO).

Conditions

  • Graves Ophthalmopathy

Interventions

DRUG

Hydroxychloroquine

Compare the effects of hydroxychloroquine 200mg twice daily for 6 months with those without treatment.

Sponsors & Collaborators

  • National Taiwan University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-21
Primary Completion
2025-09-30
Completion
2026-12-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05126147 on ClinicalTrials.gov